Introduction: The Buzz Around Anthem Biosciences IPO
The Indian IPO market continues to flourish, and this time, it’s biotech innovator Anthem Biosciences Limited stepping into the public arena with a ₹3,395 crore offer. As an end-to-end CRDMO (Contract Research, Development & Manufacturing Organization), Anthem has carved a niche in providing services across the entire drug lifecycle—an area seeing increasing demand globally.
In this blog, we’ll decode everything you need to know about the Anthem Biosciences IPO—its objectives, financial strength, competitive positioning, and most importantly, whether it deserves a spot in your portfolio.
Anthem Biosciences IPO Details
| Parameter | Details |
|---|---|
| IPO Size | ₹3,395 crore (100% Offer for Sale) |
| IPO Type | Book Building |
| Face Value | ₹2 per share |
| Price Band | [To be announced] |
| Lot Size | [To be announced] |
| Issue Type | Offer for Sale |
| Total Shares Offered | [To be updated] |
| Listing Exchange | BSE & NSE |
| Lead Manager | JM Financial Ltd |
| Registrar | KFin Technologies Ltd |
| Pre-issue Shareholding | 55,90,77,100 shares |
| Promoters | Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, Ishaan Bhardwaj |
Reservation Breakdown:
- QIB: Not more than 50%
- NII: Not less than 15%
- Retail: Not less than 35%
IPO Timeline (Tentative)
| Event | Date |
|---|---|
| IPO Open Date | [To be announced] |
| IPO Close Date | [To be announced] |
| UPI Mandate Cut-off Time | 5 PM on closing date |
| Basis of Allotment | [To be announced] |
| Initiation of Refunds | [To be announced] |
| Credit of Shares to Demat | [To be announced] |
| Listing Date | [To be announced] |
IPO Objective
Since the entire issue is an Offer for Sale (OFS):
- No fresh capital will be raised for the company.
- Proceeds will go to existing shareholders looking to partially exit.
- It’s a strategic liquidity event and also helps establish a public market for the company’s shares.
Business Model of Anthem Biosciences IPO
Anthem Biosciences operates at the heart of pharmaceutical innovation. It is among India’s fastest-growing CRDMOs, offering a one-stop solution across the drug development lifecycle—from initial discovery to full-scale manufacturing.
Key Pillars of the Business Model:
| Segment | Details |
|---|---|
| Discovery Research | 170+ ongoing projects involving 284 synthesized molecules |
| Development Services | 132 early-phase & 16 late-phase projects (drug intermediates, analogs) |
| Commercial Manufacturing | Production of APIs & intermediates for 10 commercial molecules |
| Specialty Ingredients | Probiotics, enzymes, peptides, vitamin analogues, biosimilars |
| Client Portfolio | 550+ global customers across 44+ countries (U.S., Europe, Japan, etc.) |
| IP Portfolio | 1 Indian & 7 international patents; 24 global applications pending |
| Workforce | 600+ specialists: chemists, biologists, engineers, etc. |
What sets Anthem apart is its specialized model tailored for small biotech firms, enabling them to scale from idea to commercialization using Anthem’s in-house infrastructure. This integration makes it highly cost-effective for global partners to outsource R&D and manufacturing to India.
Competitive Strengths:
- Innovation-first approach with robust IP pipeline
- Long-term relationships with diverse global clients
- High entry barriers due to technological depth
- Qualified leadership backed by scientific talent
Industry Context: Why the CRDMO Market Matters
The global pharmaceutical landscape is undergoing a massive transformation. Increasing R&D costs, regulatory complexity, and a push for faster time-to-market have led to a surge in outsourcing. This is where Contract Research, Development, and Manufacturing Organizations (CRDMOs) like Anthem Biosciences come into play.
Global Opportunity
- The global CRDMO market is projected to grow at a CAGR of over 7% through 2030.
- Biopharma companies—especially in the US and EU—are actively outsourcing complex manufacturing, discovery research, and preclinical development to Indian players.
India, with its cost advantage, scientific talent, and regulatory maturity, is quickly becoming a preferred CRDMO hub. The Anthem Biosciences IPO offers investors a direct entry into this booming outsourcing value chain.
Anthem’s Growth Levers: What Makes It Stand Out?
Anthem isn’t just another service provider. It has multiple growth engines baked into its business model:
- End-to-End Offering
Most CRDMOs operate in silos—some offer discovery, others manufacturing. Anthem offers both. This not only reduces customer acquisition costs but also increases client stickiness. - IP-Driven Innovation
With 7 global patents and 24 more in process, Anthem is not just executing client projects but also building its intellectual property base, which can translate into licensing income and valuation upside in the future. - Strong Client Relationships
The company has nurtured long-term global relationships, including with large pharma clients from Europe, the US, and Japan. This base ensures recurring revenue and volume stability. - Agility in Niche Segments
From glycolipids to biosimilars, Anthem has developed capabilities in highly specialized areas. This makes it a go-to CRDMO for biotech startups and small pharma companies that need technical excellence but lack internal infrastructure. - Scalable Platform
With a lean balance sheet and strong EBITDA margins, the company has the financial headroom to expand capacity, enhance automation, and invest in new capabilities.
Detailed SWOT Analysis
Let’s break down Anthem Biosciences’ position using a standard SWOT framework:
| Strengths | Weaknesses |
|---|---|
| Strong margins (EBITDA >36%) | Fully OFS IPO—no fund inflow for growth |
| Deep expertise in discovery and manufacturing | Limited operating history as a public company |
| Global diversified client base | High client concentration risks (to be assessed post RHP) |
| Innovation-led culture and IP base | Unlisted financials limit visibility for valuation benchmarking |
| Opportunities | Threats |
|---|---|
| CRDMO outsourcing boom globally | Regulatory changes in key markets |
| Expansion into biologics and gene therapy platforms | Currency fluctuation (USD/INR) exposure |
| Strategic acquisitions post-listing | Rising competition from China and EU |
Verdict: Anthem’s strengths and opportunities clearly outweigh its limitations. However, investors must keep an eye on execution risks and pricing at the time of IPO.
Financial Performance Snapshot (₹ in Crores)
| Period | Revenue | PAT | EBITDA | Net Worth | Debt |
|---|---|---|---|---|---|
| Sep 30, 2024 (6M) | 910.85 | 244.31 | 327.50 | 2,204.37 | 131.26 |
| FY 2023-24 | 1,483.07 | 367.31 | 519.96 | 1,924.66 | 232.53 |
| FY 2022-23 | 1,133.99 | 385.19 | 446.05 | 1,740.67 | 125.06 |
| FY 2021-22 | 1,280.24 | 405.54 | 587.31 | 1,355.00 | 35.49 |
🔎 Takeaways:
- Consistent revenue and profit generation
- Strong EBITDA margins and cash flows
- Manageable debt and improving net worth
Key Ratios
| Ratio | Value |
|---|---|
| ROE | 20.04% |
| ROCE | 25.22% |
| RoNW | 20.03% |
| PAT Margin | 24.77% |
| EBITDA Margin | 36.25% |
| Debt/Equity | 0.12 |
The strong return metrics and low leverage make Anthem financially sound and investment-worthy.
Peer Comparison of Anthem Biosciences IPO
| Company | EPS (₹) | NAV/Share (₹) | P/E | RoNW (%) | P/BV Ratio |
|---|---|---|---|---|---|
| Anthem Biosciences | 6.48 | 34.43 | — | 20.03 | — |
| Syngene Intl. | 12.71 | 105.91 | 67.23 | 12.95 | 6.69 |
| Sai Life Sciences | 4.57 | 53.83 | 168.94 | 8.89 | — |
| Suven Life Sciences | 11.80 | 80.56 | 105.67 | 15.86 | 8.46 |
| Divi’s Laboratories | 60.27 | 511.21 | 97.03 | 12.15 | 6.72 |
✅ Analysis:
- Anthem offers better RoNW than peers like Divi’s and Syngene.
- Lower EPS for now, but with room to grow as the company scales.
- No current P/E available due to unlisted status; valuation to be watched at IPO pricing stage.
What Should Retail Investors Watch Out For?
Here are five key things retail investors should monitor before applying for the Anthem Biosciences IPO:
- Final Price Band
If valuations are too aggressive (high P/E vs. peers like Syngene or Suven), listing gains may be capped. A fair pricing will drive both retail and institutional demand. - Anchor Book Response
Watch the interest from foreign and domestic institutional investors in the anchor tranche. A strong anchor book can signal confidence in long-term prospects. - Grey Market Premium (GMP)
While GMP is unofficial and volatile, a consistent premium pre-listing often indicates healthy retail interest and can help gauge short-term listing gains. - QIB & HNI Subscription
Look at how Qualified Institutional Buyers and Non-Institutional Investors bid. Higher bids in these categories often predict robust listing performance. - Post-Listing Valuation Comfort
Once listed, compare its valuation with listed peers. If it lists near Syngene’s multiples but shows better growth metrics, it might still offer a buying opportunity post-listing.
Final View: Investment Strategy
Short-Term View (Listing Gains)
If priced reasonably, the IPO could attract strong interest due to:
- Favorable sector (biotech + CRDMO = high growth)
- Strong financials and margins
- Global customer base
Expect decent listing gains if the GMP and institutional interest hold up. OFS structure could moderate excessive hype.
Long-Term View (3–5 Years)
Anthem’s IP-driven CRDMO model aligns perfectly with the global outsourcing trend in pharma. It can:
- Scale without proportionate capital increase
- Expand margins further
- Benefit from India’s low-cost, high-skill positioning
With the right execution and global expansion, Anthem could become a mid-cap biotech compounder over the next few years.
Listing Day Strategy
- Allotted? Book partial profit if gain >25%, hold remainder
- Not allotted? Watch for dips post-listing to enter around fair valuation
Conclusion
The Anthem Biosciences IPO presents a compelling mix of profitability, innovation, and global opportunity. While it is not raising fresh capital, the company is offering investors exposure to a sunrise industry via a professionally managed, tech-driven platform.
Given the company’s consistent margins, low debt, and growth-ready pipeline, it can be considered both for listing momentum and long-term wealth creation, especially if priced conservatively.
Frequently Asked Questions (FAQs)
1. What is the Anthem Biosciences IPO?
Anthem Biosciences IPO is a book-built public issue worth ₹3,395 crore. It is entirely an Offer for Sale (OFS), meaning no new shares are being issued and all proceeds will go to existing shareholders selling their stake.
2. When will the Anthem Biosciences IPO open?
The IPO dates have not been announced yet. The opening and closing dates will be updated once they are made public by the company and SEBI.
3. What is the IPO price band and lot size for Anthem Biosciences?
The IPO price band and lot size for the Anthem Biosciences IPO have not yet been disclosed. These details will be updated in the final RHP (Red Herring Prospectus).
4. Who are the promoters of Anthem Biosciences Limited?
The company is promoted by Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, and Ishaan Bhardwaj.
5. What is the business model of Anthem Biosciences?
Anthem is a CRDMO—Contract Research, Development, and Manufacturing Organization—that provides end-to-end services from drug discovery to development and commercial manufacturing. Its offerings span APIs, biosimilars, probiotics, and more.
6. Will the company receive any funds from this IPO?
No. Since the IPO is 100% an Offer for Sale, the company will not receive any proceeds. All funds will go to the selling shareholders.
7. Where will Anthem Biosciences shares be listed?
The shares will be listed on both the BSE (Bombay Stock Exchange) and NSE (National Stock Exchange).
8. What are the key financials of Anthem Biosciences?
As of FY24:
- Revenue: ₹1,483 crore
- PAT: ₹367 crore
- EBITDA Margin: 36.25%
- ROE: 20.04%
- Debt/Equity: 0.12
9. How does Anthem Biosciences compare to its listed peers like Syngene or Divi’s Labs?
While smaller in revenue, Anthem has a higher RoNW than many peers. Its margins and IP portfolio indicate strong growth potential, though valuations will determine its attractiveness at IPO time.
10. Is Anthem Biosciences IPO good for long-term investment?
It has promising fundamentals—strong margins, IP-driven innovation, and a global client base. However, long-term investors should assess the final valuation and monitor post-listing performance before holding for the long term.
11. How can I apply for the Anthem Biosciences IPO?
You can apply via your broker’s platform using UPI or ASBA (Application Supported by Blocked Amount) facility when the IPO opens. Stay tuned to your broker’s alerts for application timelines.
12. What is the expected listing gain potential?
Listing gains will depend on the final pricing, grey market sentiment (GMP), and institutional interest. Based on financials and sector interest, moderate-to-good listing gains are expected if priced reasonably.
Ad
Open FREE AngelOne Demat Account
Open a free demat and trading account. Get Free Expert Advisory for Trading and Investment.
Related Articles
China’s Fertilizer Export Halt to India: Stocks Set to Gain from the Supply Shock
Get FREEE Updates and News Straight to your inbox!
Join 100+ Subscribers for exclusive access to our Monthly Newsletter with inside Stock Market, IPO, Top Broker, Market Updates